WISE NEWECONESG

Instant commerce price war takes a toll on Meituan

Southbound Funds Increased Holdings in Meituan by 652 Million Yuan in the Last 5 Trading Days

When the City Quiets Down: A Group of Stay-Behind Riders and the 'Spring Festival Atmosphere' They Guard

JD Robots See Surge in Searches and Orders During Chinese New Year Gala

WuXi AppTec Anticipates Revenue Growth of Approximately 15.84% in 2025

Geely Auto repurchased 1.68 million shares for HKD 28.2814 million

Macquarie Recommends Buying Shares of Wuxi Biologics and Wuxi Apptec

Meituan expects 2025 loss of RMB23.3 billion to RMB24.3 billion, core local commerce division operating loss

Morgan Stanley finds Meituan's profit warning in line with expectations, maintains "Overweight" rating

Financial Regulatory Bureau et al. Urge Six Travel Platforms to Standardize Lending Practices

Jefferies: Meituan's Core Local E-commerce Business Loss Better Than Expected

Meituan Became the Most Shorted Stock by Value on the Previous Trading Day

JD Announces 1.3 Billion Yuan Investment in Employee Benefits and Five-Year Logistics Supply Chain Plan for Spring Festival

Meituan-W anticipates a loss of 23.3 billion to 24.3 billion yuan for 2024

Citigroup lowers Meituan's target price to HK$94, maintains 'Neutral' rating

Nomura maintains 'Neutral' rating on Meituan, expects stock price to have difficulty rebounding in the short term

Beijing warns tech giants to curb 'involution' amid AI giveaway war

Alibaba and Meituan Engage in Fierce Competition in Instant Retail

Sunmi Technology Passes Listing Hearing, Meituan is a Shareholder

Media highlights Meituan AI's application and problem-solving capabilities during the Spring Festival

STARCOIN GROUP

AE LOGISTICS

GUANZE MEDICAL

WATER INDUSTRY

ZHONGSHI MINAN

IDT INT'L

HAIZHI TECH GP

MANY IDEA CLOUD

FIRST CAP GP

XL2CSOPCOIN-U

Allied Market Research reports that the global deferiprone market is projected to grow from $33.4 million in 2023 to $45.9 million by 2033, at a CAGR of 3.2%. Key growth drivers include the rising prevalence of transfusion-dependent anemias, increased awareness of iron overload complications, and a preference for oral iron chelation therapies. The tablets segment dominated the market in 2023, with hospital pharmacies being the leading distribution channel. North America is expected to maintain its market dominance, while Asia-Pacific is anticipated to see significant growth due to higher thalassemia prevalence.

prnewswire

11:31 ETDeferiprone Market to Reach $45.9 Billion by 2033 Globally, at 3.2% CAGR: Allied Market Research

The global AI in Biotechnology market is projected to grow from USD 1,033 million in 2024 to USD 1,971 million by 2031, at a CAGR of 10.6%. Key growth drivers include platform-driven drug discovery, machine learning applications, and the integration of multimodal data. Trends such as generative AI for compound design, predictive analytics for clinical success, and natural language processing for data extraction are enhancing market dynamics. The shift towards computational-first pipelines and real-world data integration is central to the market's expansion, reinforcing AI's role in precision medicine and drug development.

11:23 ETAI in Biotechnology Market Size to Reach USD 1,971 Million by 2031 | Valuates Reports

The global market is experiencing growth driven by an increase in obesity rates and healthcare spending, emphasizing the need for lifestyle changes. A recent report by Allied Market Research, released on February 17, 2026 in WILMINGTON, Del., focuses on the 'Intragastric Balloons Market'. This market is expected to show significant growth in response to these factors.

Unusual Whales

Global Intragastric Balloons market set to hit $115.3M by 2033 with 13.6% CAGR, driven by obesity rates rise and healthcare spending surge.

EchoNous has announced a significant expansion of its Kosmos platform, enhancing its AI-driven point-of-care ultrasound capabilities. The update introduces advanced OB/GYN features and new vascular workflows, allowing clinicians to perform comprehensive measurements and billable studies at the bedside. This expansion aims to bridge the gap between portability and performance, providing essential tools for clinicians in various settings, from tertiary hospitals to resource-limited clinics. The new software is available for download on the Apple App Store.

SPDR S&P Software

iShares Expanded Tech Software Sector ETF

08:55 ETEchoNous Unveils Major Kosmos Expansion, Bringing Robust OB/GYN and Vascular Tools to AI-Enhanced Ultrasound Platform

A rising trend of parents rejecting vitamin K shots for newborns is causing concern among health professionals. This decision, influenced by vaccine skepticism and misinformation, poses risks as vitamin K is essential for preventing serious bleeding disorders in infants. Medical experts are alarmed by the potential consequences and are urging parents to consider the scientific evidence supporting the safety and necessity of these injections, which have been standard practice for decades.

CoinLive

Concerns Rise as Parents Reject Vitamin K Shots for Newborns

DXCM

TNDM

BJDX

CODX

SENS

A recent study by Credence Research Inc. revealed insights on the Blood Glucose Monitoring Devices Market. The market is anticipated to experience significant growth, increasing from USD 16,202.5 million in 2024 to a projected USD 36.8 billion by the year 2032. This growth represents a Compound Annual Growth Rate (CAGR) that signifies a substantial expansion in the market over the forecast period.

DexCom

Tandem Diabetes

Bluejay Diagnostics

Abbott Laboratories

Co-Diagnostic

Medtronic

Senseonics

Blood Glucose Monitoring Devices Market projected to hit USD 36.8 billion by 2032, fueled by CGM adoption and home diagnostics.

The global market growth is being driven by a surge in traumatic brain injuries (TBIs) incidents, an increase in demand for minimally invasive procedures, and a growing geriatric population. These factors have led to a rise in market demand. A report published by Allied Market Research in Wilmington, Delaware on February 16, 2026 highlighted these trends.

Global ICP monitoring market to reach $0.6B by 2033, growing at 5.1% CAGR, driven by TBIs, minimally invasive procedures, and aging population.

The Intracranial Pressure (ICP) Monitoring Market is projected to grow from $0.4 billion in 2023 to $0.6 billion by 2033, at a CAGR of 5.1%. Key growth drivers include the rise in traumatic brain injuries, demand for minimally invasive procedures, and an increasing geriatric population. However, high device costs may hinder growth. Technological advancements and untapped markets in developing economies present opportunities for expansion. The report covers various techniques, applications, and end users, highlighting the importance of ICP monitoring in managing severe head injuries and neurological conditions.

10:16 ETIntracranial Pressure (ICP) Monitoring Market to Reach $0.6 Billion by 2033 Globally, at 5.1% CAGR: Allied Market Research

VRTX

The global pain market presents significant opportunities for innovation, particularly in developing non-addictive alternatives to opioids. Currently, 98% of globally approved pain drugs are generics, with a lack of diversity in treatment options. The recent approval of Vertex Pharmaceuticals’ Journavx marks a breakthrough, but it still falls short in effectiveness compared to opioids. As of January 2026, 590 drugs are in development, with a focus on novel targets and modalities, including voltage-gated sodium channel inhibitors and neuromodulation techniques. Challenges include subjective pain assessment and high placebo response rates, but regulatory incentives and innovative trial designs are fostering interest in the market.

Pharmaceutical Technology

Vertex Pharma

Significant opportunities exist in the global pain market for novel mechanisms and modalities

ARKG

An initial sum of $200 million has been received upfront, with the possibility of an additional $200 million in proceeds. This funding is anticipated to cover the costs associated with finalizing the Phase 3 ENSURE trials for relapsing multiple sclerosis, commencing the Phase 3 trial for primary progressive multiple sclerosis, and facilitating the transition into the next phase of the project.

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

VG Health

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

iShares Global Healthcare

Proshares Ultra Nasdaq Biotech

Immunic

VanEck Biotech ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

iShares US Pharma

Immunic raises USD 200 million in private placement, with potential for up to USD 200 million more. Funds to support Phase 3 trials and transition to commercial-stage company.

FTXG

INGR

According to a Mordor Intelligence report, the global modified starch market is projected to grow from USD 17.15 billion in 2026 to USD 19.90 billion by 2031, with a CAGR of 2.67%. North America leads the market with 34% revenue share, driven by rising demand in food processing and pharmaceuticals. Key trends include clean label innovations and sustainability efforts, particularly in plant-based and dairy sectors. The Asia-Pacific region is expected to grow the fastest due to industrialization and food processing expansion. Major players include Roquette Freres, Ingredion, and Cargill.

First Trust NASDAQ Food & Beverage

Ingredion

Conagra Brands

Invesco Food & Beverage ETF

04:01 ETNorth America Leads the Modified Starch Market with 34% Revenue in 2025 as Global Market Size Set to Surpass 19.90B by 2031 says a 2026 Mordor Intelligence Report

The BCL-2 inhibitors market is projected to experience significant growth from 2025 to 2034, driven by rising cancer incidence and the introduction of new therapies like Lisaftoclax and Sonrotoclax. DelveInsight's report highlights the increasing demand for targeted treatments in hematologic malignancies, with the U.S. expected to dominate the market. Key players include Ascentage Pharma and BeOne Medicines, with ongoing clinical trials for next-generation inhibitors. The market's expansion is supported by a shift towards precision medicine and the effectiveness of BCL-2 inhibitors in combination therapies.

BeOne Medicines

Ascentage Pharma

Beigene

Invesco Nasdaq Biotechnology ETF

17:31 ETBCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsight

The global Alzheimer's therapeutics market is projected to grow from USD 4.3 billion in 2026 to USD 10.4 billion by 2036, with a CAGR of 9.3%. This growth is driven by a shift towards disease-modifying immunotherapies, such as anti-amyloid therapies, which aim to slow disease progression. Hospital pharmacies are becoming central to distribution, holding 35% market share. Key growth markets include Japan and India, while Donepezil remains the leading drug. The market is evolving with advancements in diagnostics and multi-mechanism therapies, as pharmaceutical companies increase R&D investments.

MorningStar

Alzheimer's Therapeutics Market to Reach USD 10.4 Billion by 2036 as Disease-Modifying Immunotherapies Transform Treatment Paradigms

BBIO

The PROPEL 3 study achieved success by meeting the primary goal of demonstrating a significant change in AHV compared to baseline at Week 52, with a p-value of less than 0.0001.

Bridgebio Pharma

BridgeBio's Phase 3 trial of Oral Infigratinib in Achondroplasia shows significant body proportionality improvement, hitting primary endpoint (p<0.0001) - AHV at Week 52.

Claritas Rx has released a whitepaper titled "Thriving in Turbulence: Strategic Adaptation in the Evolving Specialty and Rare Market," addressing challenges for specialty and rare disease manufacturers. It outlines five key trends expected for 2026, including rising economic volatility, tariff risks, and shifts in payer dynamics, aiming to assist manufacturers in developing strategic agility in response to these complexities.

"Data deluge" trend in 2026 with increasing data providers, Claritas Rx white paper on specialty and rare market trends.

WISE NEWECONESG(03182.HK)

11:31 ETDeferiprone Market to Reach $45.9 Billion by 2033 Globally, at 3.2% CAGR: Allied Market Research

11:23 ETAI in Biotechnology Market Size to Reach USD 1,971 Million by 2031 | Valuates Reports

Global Intragastric Balloons market set to hit $115.3M by 2033 with 13.6% CAGR, driven by obesity rates rise and healthcare spending surge.

08:55 ETEchoNous Unveils Major Kosmos Expansion, Bringing Robust OB/GYN and Vascular Tools to AI-Enhanced Ultrasound Platform

Concerns Rise as Parents Reject Vitamin K Shots for Newborns